Refined tools for the treatment of hepatocellular carcinoma
Open Access
- 31 May 2005
- journal article
- editorial
- Published by Elsevier in Journal of Hepatology
- Vol. 42 (5) , 629-631
- https://doi.org/10.1016/j.jhep.2005.02.006
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Systemic efficacy of combined suicide/cytokine gene therapy in a murine model of hepatocellular carcinomaJournal of Hepatology, 2005
- Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivoPublished by Elsevier ,2005
- Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II studyBritish Journal of Cancer, 2005
- Introduction: The burden of hepatocellular carcinomaGastroenterology, 2004
- Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differencesDrug Resistance Updates, 2003
- Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene / Ganciclovir System: Fifteen Years of ApplicationCurrent Gene Therapy, 2003
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinomaJournal of Hepatology, 2000
- A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinomaAnnals of Oncology, 2000
- Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticlesInvestigational New Drugs, 1992